Genflow Biosciences PLC Announces Holding(s) in Company

Genflow Biosciences (OTC:GENFF) major-holdings notice: Jonathan Mark Swann crossed a regulatory threshold, increasing his direct voting stake to 12.13% of voting rights (59,861,278 votes) on 23-Jan-2026.

Rhea-AI Summary

Genflow Biosciences (OTC:GENFF) major-holdings notice: Jonathan Mark Swann crossed a regulatory threshold, increasing his direct voting stake to 12.13% of voting rights (59,861,278 votes) on 23-Jan-2026. The issuer notified the market on 25-Jan-2026 and the completion date is listed as 24-Jan-2026.

The filing shows a prior position of 11.32% (55,861,278 votes), no voting rights via financial instruments, and no additional information disclosed.

Positive

• Direct stake reached 12.13% of voting rights on 23-Jan-2026
• Total direct voting rights reported at 59,861,278 shares

Negative

• None.

Argus Session date unavailable

-29.43% session move Open Argus

Details

News Market Reaction – GENFF

The recorded move for GENFF in the trading session of this news was -29.43%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LONDON, UK / ACCESS Newswire / January 30, 2026 / TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BP2C3V08

Issuer Name

GENFLOW BIOSCIENCES PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Jonathan Mark Swann

City of registered office (if applicable)

rickmansworth

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

City of registered office (if applicable)

Country of registered office (if applicable)

5. Date on which the threshold was crossed or reached

23-Jan-2026

6. Date on which Issuer notified

25-Jan-2026

7. Total positions of person(s) subject to the notification obligation

	% of voting rights attached to shares (total of 8.A)	% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)	Total of both in % (8.A + 8.B)	Total number of voting rights held in issuer
Resulting situation on the date on which threshold was crossed or reached	12.130000	0.000000	12.130000	59861278
Position of previous notification (if applicable)	11.320000	0.000000	11.320000	55861278

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)	Number of direct voting rights (DTR5.1)	Number of indirect voting rights (DTR5.2.1)	% of direct voting rights (DTR5.1)	% of indirect voting rights (DTR5.2.1)
GB00BP2C3V08	59861278	0	12.130000	0.000000
Sub Total 8.A	59861278		12.130000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument	Expiration date	Exercise/conversion period	Number of voting rights that may be acquired if the instrument is exercised/converted	% of voting rights
Sub Total 8.B1

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument	Expiration date	Exercise/conversion period	Physical or cash settlement	Number of voting rights	% of voting rights
Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person	Name of controlled undertaking	% of voting rights if it equals or is higher than the notifiable threshold	% of voting rights through financial instruments if it equals or is higher than the notifiable threshold	Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional Information

None

12. Date of Completion

24-Jan-2026

13. Place Of Completion

London

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Genflow Biosciences PLC

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stake did Jonathan Mark Swann report in Genflow Biosciences (GENFF) on 23-Jan-2026?

He reported a 12.13% direct voting stake, equal to 59,861,278 votes. According to the company, this crossed the notifiable threshold on 23-Jan-2026 and was notified to the market on 25-Jan-2026.

How much did Jonathan Mark Swann's holding in GENFF change from the previous notification?

His direct holding increased from 11.32% to 12.13%, a rise of 0.81 percentage points. According to the company, the prior number of voting rights was 55,861,278 versus 59,861,278 after the change.

Were any financial instruments reported by Jonathan Mark Swann in the GENFF notification?

No financial instruments were reported; the filing shows 0.00% via derivatives. According to the company, all disclosed voting rights are direct holdings with no indirect or instrument-based percentages.

When did Genflow Biosciences (GENFF) receive the major-holdings notification about Jonathan Mark Swann?

The issuer was notified on 25-Jan-2026. According to the company, the threshold crossing date was 23-Jan-2026 with a listed completion date of 24-Jan-2026.

What is the significance of a 12.13% holding in Genflow Biosciences (GENFF)?

A 12.13% holding represents a notifiable, substantial direct stake in the issuer. According to the company, the notice records voting rights, prior position, and confirms no financial instruments affecting the percentage.